{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T04:16:21Z","timestamp":1762748181619,"version":"build-2065373602"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.1093\/jnci\/djaf231","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:21:45Z","timestamp":1756120905000},"page":"2154-2155","source":"Crossref","is-referenced-by-count":0,"title":["Unstacking the deck in follicular lymphoma clinical trials"],"prefix":"10.1093","volume":"117","author":[{"given":"Samuel","family":"Yamshon","sequence":"first","affiliation":[{"name":"Division of Hematology & Medical Oncology, Weill Cornell Medicine , New York, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-1115","authenticated-orcid":false,"given":"John P","family":"Leonard","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health and NYU Grossman School of Medicine , New York, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"2025110923141312400_djaf231-B1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.17436","article-title":"Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years","volume":"193","author":"Loh","year":"2021","journal-title":"Br J Haematol"},{"key":"2025110923141312400_djaf231-B2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"key":"2025110923141312400_djaf231-B3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2024-201626","article-title":"Efficacy, toxicity, and predictors of outcomes with CD3-CD20 Bi-specific antibodies post CAR T-cell failure for aggressive B-cell lymphoma","volume":"144","author":"Melody","year":"2024","journal-title":"Blood"},{"key":"2025110923141312400_djaf231-B4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf174","article-title":"Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival","author":"Wong","year":"2025","journal-title":"JNCI: J Nat Cancer Inst"},{"key":"2025110923141312400_djaf231-B5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025110923141312400_djaf231-B6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2025110923141312400_djaf231-B7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"New Engl J Med"},{"key":"2025110923141312400_djaf231-B8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"New Engl J Med"},{"key":"2025110923141312400_djaf231-B9","article-title":"Cancer clinical trial eligibility criteria: performance status: guidance for industry, IRBs, and clinical investigators","author":"FDA","year":"2024","journal-title":"Draft Guid"},{"key":"2025110923141312400_djaf231-B10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025110923141312400_djaf231-B11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3109\/10428194.2014.953144","article-title":"Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States","volume":"56","author":"Nastoupil","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025110923141312400_djaf231-B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026978","article-title":"End points and outcomes in follicular lymphoma: what should we measure, how, and why?","author":"Di","year":"2025","journal-title":"Blood"},{"key":"2025110923141312400_djaf231-B13","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf231\/64259837\/djaf231.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2154\/64259837\/djaf231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2154\/64259837\/djaf231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T04:14:17Z","timestamp":1762748057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/11\/2154\/8253283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":13,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf231","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"type":"print","value":"0027-8874"},{"type":"electronic","value":"1460-2105"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,12]]}}}